Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of THR-1442 compared to Dapagliflozin
as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with
type 2 diabetes mellitus (T2DM).